Autopsy report · NCT01814904

Dose-finding Study of MCI-196

“This study has been terminated because of insufficient patient recruitment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 1 month before it started.
• Ran for about 9 months before it stopped.
• 10 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Tanabe Pharma Corporation

Sponsor type

Industry

Conditions

Chronic Kidney Disease; Dialysis; Hyperphosphatemia; Paediatric

Interventions

colestilan-L; colestilan-M; colestilan-H; CBPB

Participants

10

Sites

1

Countries

United Kingdom

Trials that died the same way

• Aspirin as a Novel Anti-Inflammatory Modality in the Fontan Patients
  “This study was terminated due to inability to recruit sufficient patients.” (90% match in meaning)
• Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF
  “The study was terminated due to difficulty in recruiting patients.” (89% match in meaning)
• A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression
  “Study terminated due to slow patient recruitment.” (89% match in meaning)
• All-On-4® Treatment Concept
  “The study stopped as the performance of the study showed insufficient patient recruitment.” (87% match in meaning)
• Ultrasound-guided Hydrosalpinx Aspiration During Egg Collection
  “The study was terminated because it is very difficult to recruit more patients.” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.